Morphine Sulfate extended-Release Tablets, USP; 30 mg, 100-count bottles, Rx only, manufactured b...
FDA Drug Recall #D-1187-2022 — Class I — June 17, 2022
Recall Summary
| Recall Number | D-1187-2022 |
| Classification | Class I — Serious risk |
| Date Initiated | June 17, 2022 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Bryant Ranch Prepack, Inc. |
| Location | Burbank, CA |
| Product Type | Drugs |
Product Description
Morphine Sulfate extended-Release Tablets, USP; 30 mg, 100-count bottles, Rx only, manufactured by: Ohm Laboratories Inc., New Brunswick NJ 08901 USA; Relabeled by: Bryant Ranch Prepack, Inc., Burbank, CA, 91504 USA, NDC: 63629-1088-01.
Reason for Recall
Labeling: Label Mix-up: bottles labeled as Morphine Sulfate 60 mg Extended-Release tablets contain Morphine Sulfate 30 mg Extended-Release tablets and bottles labeled as Morphine Sulfate 30 mg Extended-Release tablets may contain Morphine Sulfate 60 mg Extended-Release tablets.
Distribution Pattern
Distributed to one wholesaler in AL for further distribution in the US.
Lot / Code Information
Lot #: 179642, Exp. Date 11/30/2023.
Other Recalls from Bryant Ranch Prepack, Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0537-2024 | Class III | Cephalexin for Oral Suspension, USP, 125mg per ... | May 10, 2024 |
| D-0539-2024 | Class III | Cephalexin for Oral Suspension, USP, 250mg per ... | May 10, 2024 |
| D-0538-2024 | Class III | Cephalexin for Oral Suspension, USP, 250mg/ 5mL... | May 10, 2024 |
| D-0540-2024 | Class III | Cephalexin for Oral Suspension, USP, 250mg/5mL,... | May 10, 2024 |
| D-0536-2024 | Class III | Cephalexin for Oral Suspension, USP, 125mg per ... | May 10, 2024 |
Frequently Asked Questions
Stop using the medication immediately and contact your pharmacist. A mislabeling recall can range from a minor technical error (wrong font size) to a serious mix-up where one drug is inside another drug's packaging. If you received a medication that looks or acts differently than expected, or if you experienced unexpected effects, tell your doctor immediately. The pharmacist can verify whether your specific lot is affected and provide a replacement. Report any adverse effects experienced to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.